Washington Capital Management Inc. Has $1.12 Million Stock Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Washington Capital Management Inc. lowered its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH) by 2.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 4,875 shares of the medical research company’s stock after selling 125 shares during the period. Laboratory Co. of America comprises 0.9% of Washington Capital Management Inc.’s holdings, making the stock its 20th largest holding. Washington Capital Management Inc.’s holdings in Laboratory Co. of America were worth $1,118,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Private Trust Co. NA raised its stake in Laboratory Co. of America by 3.2% during the third quarter. Private Trust Co. NA now owns 1,342 shares of the medical research company’s stock worth $300,000 after buying an additional 41 shares during the last quarter. Empirical Finance LLC raised its position in shares of Laboratory Co. of America by 1.7% in the 3rd quarter. Empirical Finance LLC now owns 3,055 shares of the medical research company’s stock worth $683,000 after acquiring an additional 50 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Laboratory Co. of America by 16.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 354 shares of the medical research company’s stock valued at $81,000 after purchasing an additional 50 shares during the period. Concord Wealth Partners boosted its position in shares of Laboratory Co. of America by 43.3% during the 3rd quarter. Concord Wealth Partners now owns 172 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 52 shares in the last quarter. Finally, Rehmann Capital Advisory Group boosted its position in shares of Laboratory Co. of America by 1.9% during the 3rd quarter. Rehmann Capital Advisory Group now owns 2,844 shares of the medical research company’s stock valued at $637,000 after purchasing an additional 53 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Laboratory Co. of America Trading Down 0.9 %

Shares of LH opened at $246.36 on Thursday. Laboratory Co. of America Holdings has a 1-year low of $191.97 and a 1-year high of $250.56. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.66. The firm’s 50-day moving average price is $235.43 and its 200-day moving average price is $227.96. The firm has a market capitalization of $20.61 billion, a price-to-earnings ratio of 47.65, a PEG ratio of 1.81 and a beta of 1.06.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 55.71%.

Analysts Set New Price Targets

A number of analysts recently commented on the company. StockNews.com lowered Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Jefferies Financial Group reaffirmed a “buy” rating and set a $275.00 target price (up from $265.00) on shares of Laboratory Co. of America in a research report on Tuesday, December 10th. Evercore ISI upgraded Laboratory Co. of America from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $260.00 to $265.00 in a report on Tuesday, January 7th. Barclays boosted their price target on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the company an “equal weight” rating in a research note on Friday, October 25th. Finally, UBS Group dropped their price objective on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a research note on Tuesday. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $261.77.

Insider Buying and Selling at Laboratory Co. of America

In related news, CEO Adam H. Schechter sold 6,189 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $243.47, for a total transaction of $1,506,835.83. Following the sale, the chief executive officer now directly owns 87,441 shares of the company’s stock, valued at $21,289,260.27. This trade represents a 6.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kerrii B. Anderson sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $235,000.00. Following the sale, the director now directly owns 12,722 shares in the company, valued at approximately $2,989,670. The trade was a 7.29 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,572 shares of company stock worth $5,915,209. 0.85% of the stock is owned by insiders.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.